Conference Day 1
Wednesday 21st June 2023
8:00 am Registration
8:50 am
Chair’s Opening Remarks
Exploring the Inhalation Landscape for Next Generation Development
9:00 am Panel Discussion: Setting Up Context: Capitalizing on the Current Wave of Inhaled Delivery
Synopsis
With renewed interest sparked by COVID-19, unmet clinical needs and better formulation technologies, inhaled
delivery offers key advantages over other routes of administration for targeted local delivery. In this panel
discussion, experts will explore:
- Reflecting on COVID-19, renewed interest and novel technologies
- Formulating biologics for inhaled delivery such as mRNA
- Discussing advantages of inhalation to overcome systemic toxicity issues with bypass of the liver
9:45 am Challenges & Considerations for the Transition to Low Global Warming Potential (LGWP) Propellants with Metered Dose Inhalers
Synopsis
- Discussing the scientific understanding of propellants and their impact on MDI performance
- Overview of the previous PFC to HFA propellant transition and lessons learned
- Understanding the current LGWP propellant transition and the potential challenges and considerations this may present for MDI developers
10:15 am Inspired Products: Putting the Patient at the Center of Inhaled Therapeutic Development
Synopsis
- Understanding opportunities to enhance outcomes via the inhaled route of administration
- Considering patient needs and context to optimize drug delivery
- Case studies illustrating key principles for the development of inhaled therapeutics
Optimizing Inhalation Administration for Targeted Delivery to the Lung
10:45 am
Morning Break & Speed Networking
Synopsis
Enjoy a morning coffee while networking with industry experts
11:45 am Stably Aerosolized Lipid-mRNA Nanoparticles Towards Targeted Pulmonary Delivery
Synopsis
- Understand the current work and identify challenges in delivery with lipid nanoparticles for nucleic acid delivery to extrahepatic tissues, in particular the lungs
- Analyze and assess composition of formulations and methods of delivery to achieve effective nucleic acid delivery throughout airways
- Identify targeting moieties and compositions that target airway epithelia
12:15 pm Roundtable Discussion: Specific Targeted Delivery for Deep Lung Tissue & Improving Bioavailability
Synopsis
- Understanding how to target specific cell types in the lung depending on your disease indication – CF, COPD, IPF
- How to promote target engagement with specific receptors and cell types for optimized therapeutic effects
- Exploring how your disease can impact the deposition in the lung
1:00 pm
Networking Lunch
2:00 pm Anticalin Platform for Development of Inhaled Therapies in Chronic Airway Disease
Synopsis
- Bullet points: inhaled Anticalin antagonists for respiratory disease
- Benefits of local intervention via inhalation versus systemic administration
- Development of PRS-060, a potential first-in-class, inhaled IL-4Ra inhibitor for the treatment of asthma
2:30 pm Overcoming Development Challenges of Inhaled Liposomal Formulations
Synopsis
- Discussing the advantages of use liposomal formulations
- Assessing challenges with developing liposomal formulations
- Outlining a case study of ALIS (Amikacin Liposome Inhalation Suspension)
3:00 pm
Afternoon Break
3:45 pm Using Polymeric Nanoparticles for Delivery of Biologics
Synopsis
- Delving into the use of polymer formulations for RNA delivery to the lungs and their advantage of temperature resistance, and rigidity
- Outlining how polymers are best suited to navigate through the mucus
- How do polymeric nanoparticles help in overcoming chemical and biological barriers to deliver to the lung?
4:15 pm Fireside Chat: Exploring Modalities & Innovations: Delivering Biologics vs Small Molecules vs Nanoparticles
Synopsis
With a historic prevalence of delivering small molecules via the inhalation route, what are the key differences
and considerations when delivering biologics such as mRNA, DNA, peptides and nanoparticle-mediated delivery compared with small molecules.
Join this panel discussion to understand:
- Formulation considerations of small molecules vs biologics
- Specific target engagement: small molecules are not that specific resulting in unwanted side effects
- Shear force and bioactivity: understanding that macromolecules are more susceptible to shear force and their solid / chemical stability needs to be protects
- Using nanoparticles for delivery: particle aggregation and immune response